Landscape Capital Management L.L.C. Buys New Position in The Chemours Company $CC

Landscape Capital Management L.L.C. purchased a new position in The Chemours Company (NYSE:CC) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 41,908 shares of the specialty chemicals company’s stock, valued at approximately $860,000.

Several other large investors also recently bought and sold shares of the company. Allworth Financial LP acquired a new position in shares of Chemours during the second quarter worth $51,000. Avaii Wealth Management LLC purchased a new stake in Chemours during the 2nd quarter worth $6,139,000. BlackRock Inc. purchased a new stake in Chemours during the 2nd quarter worth $477,769,000. Deutsche Bank AG acquired a new position in Chemours in the 2nd quarter worth $3,291,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Chemours in the 2nd quarter worth $1,467,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CC. BMO Capital Markets dropped their target price on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a research report on Thursday, August 13th. Mizuho set a $22.00 price target on Chemours in a report on Wednesday, August 5th. Truist Financial lowered their price objective on Chemours from $30.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Weiss Ratings downgraded Chemours from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, August 6th. Finally, Zacks Research downgraded Chemours from a “strong-buy” rating to a “strong sell” rating in a report on Tuesday, August 11th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $20.10.

Insider Transactions at Chemours

In other news, insider Calderon Gerardo Familiar bought 1,935 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was bought at an average price of $15.53 per share, for a total transaction of $30,050.55. Following the transaction, the insider owned 58,547 shares in the company, valued at $909,234.91. The trade was a 3.42% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Shane Hostetter purchased 3,350 shares of the stock in a transaction dated Thursday, August 6th. The stock was purchased at an average price of $14.94 per share, with a total value of $50,049.00. Following the completion of the acquisition, the chief financial officer directly owned 102,698 shares in the company, valued at approximately $1,534,308.12. The trade was a 3.37% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders bought 8,663 shares of company stock worth $130,601. 0.85% of the stock is currently owned by corporate insiders.

Key Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $2.05 from $1.95 and increased Q4 2027 EPS to $0.61 from $0.53, suggesting improved profitability may emerge beyond 2026.
• Positive Sentiment: The firm also lifted estimates for Q1 2027 EPS to $0.40 from $0.39, Q3 2027 EPS to $0.58 from $0.56, Q1 2028 EPS to $0.56 from $0.55, and Q2 2028 EPS to $0.65 from $0.61.
• Neutral Sentiment: The revisions indicate a potentially stronger longer-term earnings trajectory, but they are offset by weaker expectations for the company’s immediate results. Zacks’ current full-year EPS consensus is approximately $0.87.
• Negative Sentiment: Zacks cut its FY2026 EPS forecast to $0.83 from $0.90 and reduced Q4 2026 EPS to $0.11 from $0.12, signaling pressure on near-term earnings.
• Negative Sentiment: The largest revision was a reduction in Q3 2026 EPS to $0.25 from $0.41. That forecast implies a substantial decline from the previous estimate and could weigh on investor sentiment.
• Negative Sentiment: FY2028 EPS was also lowered to $2.31 from $2.38, indicating that longer-term optimism is not broad-based. Chemours recently missed quarterly revenue and EPS expectations, adding to concerns about operating momentum.

Chemours Stock Performance

Shares of Chemours stock opened at $15.96 on Monday. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The Chemours Company has a 1 year low of $10.44 and a 1 year high of $28.67. The firm’s 50-day simple moving average is $18.01 and its 200-day simple moving average is $20.05. The firm has a market cap of $2.40 billion, a PE ratio of -8.36 and a beta of 1.43.

Chemours (NYSE:CC) last posted its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.65 billion. Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter last year, the business posted ($2.54) earnings per share. Equities analysts forecast that The Chemours Company will post 0.87 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, August 14th. Chemours’s dividend payout ratio (DPR) is currently -18.32%.

Chemours Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.